AKBA
Akebia Therapeutics, Inc.
AKBA offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over AKBA overall, supported by stronger fundamentals and lower modeled downside.
AKBA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Stable | |
| Strong |
AKBA's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AKBA PE Valuation
AKBA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AKBA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect AKBA's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over AKBA on the outlook, with more favorable earnings and revenue expectations.
AKBA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.16 | -$0.09 |
| Q2 2026 | -$0.11 | +$0.06 |
| Q1 2026 | -$0.08 | +$0.13 |
| Q4 2025 | -$0.02 | +$0.31 |
| Q3 2025 | -$0.07 | +$0.15 |
| Q2 2025 | -$0.17 | +$0.03 |
| Q1 2025 | -$0.21 | +$0.01 |
| Q4 2024 | -$0.33 | -$0.06 |
AKBA lost $0.16 per share over the past year, and its loss has widened in each of the last three quarters.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AKBA on earnings quality, reporting a profit while its opponent remains loss making.
AKBA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $36.9M | -37% |
| Q2 2026 | $49.1M | -21% |
| Q1 2026 | $53.5M | -6.6% |
| Q4 2025 | $57.6M | +24% |
| Q3 2025 | $58.8M | +57% |
| Q2 2025 | $62.5M | +43% |
| Q1 2025 | $57.3M | +76% |
| Q4 2024 | $46.5M | -17% |
AKBA's revenue has slid since its 2022 peak: $37M last quarter, down 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -31% | -39 points |
| Q2 2026 | -13% | -35 points |
| Q1 2026 | -8.8% | -32 points |
| Q4 2025 | -15% | +16 points |
| Q3 2025 | 7.6% | +41 points |
| Q2 2025 | 23% | +43 points |
| Q1 2025 | 24% | +69 points |
| Q4 2024 | -31% | -33 points |
AKBA's operating margin was −31% last quarter, down 39 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AKBA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AKBA on profitability, with a higher operating margin.
AKBA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.6M | -94% |
| Q2 2026 | $2.4M | -89% |
| Q1 2026 | -$21.3M | -$7.7M |
| Q4 2025 | $31.1M | +$35.5M |
| Q3 2025 | $28M | +$34.7M |
| Q1 2025 | -$13.6M | +$5.8M |
| Q4 2024 | -$4.5M | -$2.2M |
| Q3 2024 | -$6.7M | +$470K |
AKBA has burned cash in most quarters: $14M over the past year, down 57% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AKBA on cash flow, with more consistent year-over-year improvement.
AKBA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +7.3M shares |
| 1 year | +0.9% | +2.5M shares |
| 3 years | +47% | +88.6M shares |
| 5 years | +59% | +103M shares |
| Available history | +132% | +158M shares |
AKBA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AKBA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -17.3x | Net Cash |
| Q4 2025 | -5.5x | Net Cash |
| Q3 2025 | -4.2x | Net Cash |
| Q2 2025 | -4.5x | Net Cash |
| Q1 2025 | -10.5x | Net Cash |
| Q3 2024 | 1.6x | Healthy |
AKBA has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AKBA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 14.7 | Oversold |
AKBA's weekly RSI is 33 (neutral) and its Stochastic is 15 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AKBA PE vs Healthcare Sector
AKBA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AKBA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.68 | 26% below |
| 20 week MA | $0.92 | 46% below |
| 50 week MA | $1.16 | 57% below |
| 100 week MA | $1.88 | 73% below |
| 200 week MA | $1.56 | 68% below |
AKBA is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AKBA on trend strength, trading above more of its moving averages.
AKBA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.52 | $2.92 | -55% |
| 2021 | $2.92 | $2.53 | -13% |
| 2022 | $2.53 | $0.43 | -83% |
| 2023 | $0.43 | $1.24 | +188% |
| 2024 | $1.24 | $1.95 | +57% |
| 2025 | $1.95 | $1.66 | -15% |
| 2026 YTD | $1.66 | $0.50 | -70% |
AKBA's yearly returns have swung widely, from +188% in 2023 to −83% in 2022. It's down 70% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AKBA on returns for 2026, with the stronger performance.